by Transplantation and Cellular Therapy
Efmarodocokin alfa, an interleukin-22 agonist, demonstrates potential as prophylaxis against acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation...
by Transplantation and Cellular Therapy
A retrospective study underscores the value of contemporary grading systems for interpreting post–chimeric antigen receptor (CAR) T-cell therapy outcomes.
by Clinical Cancer Research
Scientists are encouraged by early findings that point to preferentially expressed antigen in melanoma (PRAME) as a feasible alternative to usual chimeric antigen receptor (CAR) T-cell therapy for...
by Cytotherapy
Regulatory T-cells (Tregs), especially when modified to express a chimeric antigen receptor (CAR), are attracting attention for their potential therapeutic value in the setting of autoimmune,...
by Blood Advances
Researchers say promising Phase I evidence justifies advanced clinical trials to investigate the use of arlocabtagene autoleucel (arlo-cel) in patients with heavily pretreated relapsed or...
by Blood Advances
Researchers report that further study is warranted after baricitinib achieved significant durable response in a small sample of patients with refractory severe chronic graft-versus-host disease...